- Home
- LIEN vs HRTX Comparison
LIEN vs HRTX Comparison
Compare LIEN & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIEN
- HRTX
- Stock Information
- Founded
- LIEN 2021
- HRTX 1983
- Country
- LIEN United States
- HRTX United States
- Employees
- LIEN N/A
- HRTX N/A
- Industry
- LIEN
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- LIEN
- HRTX Health Care
- Exchange
- LIEN NYSE
- HRTX Nasdaq
- Market Cap
- LIEN 234.6M
- HRTX 350.4M
- IPO Year
- LIEN 2022
- HRTX 1987
- Fundamental
- Price
- LIEN $10.10
- HRTX $2.17
- Analyst Decision
- LIEN Hold
- HRTX Strong Buy
- Analyst Count
- LIEN 1
- HRTX 2
- Target Price
- LIEN N/A
- HRTX $5.50
- AVG Volume (30 Days)
- LIEN 16.8K
- HRTX 1.8M
- Earning Date
- LIEN 05-14-2025
- HRTX 05-06-2025
- Dividend Yield
- LIEN 13.59%
- HRTX N/A
- EPS Growth
- LIEN N/A
- HRTX N/A
- EPS
- LIEN 0.93
- HRTX N/A
- Revenue
- LIEN $21,665,753.00
- HRTX $148,518,000.00
- Revenue This Year
- LIEN $102.44
- HRTX $11.18
- Revenue Next Year
- LIEN N/A
- HRTX $13.15
- P/E Ratio
- LIEN $10.77
- HRTX N/A
- Revenue Growth
- LIEN 81.56
- HRTX 12.43
- 52 Week Low
- LIEN $9.71
- HRTX $1.04
- 52 Week High
- LIEN $13.38
- HRTX $3.93
- Technical
- Relative Strength Index (RSI)
- LIEN N/A
- HRTX 49.30
- Support Level
- LIEN N/A
- HRTX $2.00
- Resistance Level
- LIEN N/A
- HRTX $2.61
- Average True Range (ATR)
- LIEN 0.00
- HRTX 0.18
- MACD
- LIEN 0.00
- HRTX 0.01
- Stochastic Oscillator
- LIEN 0.00
- HRTX 45.00
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company is an externally managed, closed-end, non-diversified management investment company with an investment objective to maximize risk-adjusted returns on equity for its stockholders by investing in direct loans to privately held middle-market companies, with a focus on cannabis companies.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.